U.t.i as per 2nf year mbbs pharma

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

I now have all the material needed for a thorough 2nd year MBBS pharmacology answer on UTI. Here is the complete write-up:

Urinary Tract Infections (UTI) - Pharmacology (2nd Year MBBS)

1. Introduction & Common Pathogens

UTIs are among the most common bacterial infections worldwide, primarily affecting women and the elderly. The most frequent causative organisms are:

E. coli (most common, ~80%)
Klebsiella pneumoniae
Staphylococcus saprophyticus (young sexually active women)
Enterococcus faecalis
Proteus mirabilis
Pseudomonas aeruginosa (hospital-acquired, catheter-associated)

2. Classification of UTI

Type	Location	Example
Lower UTI	Bladder/urethra	Cystitis, urethritis
Upper UTI	Kidney/ureters	Pyelonephritis
Uncomplicated	Healthy, non-pregnant women	Simple cystitis
Complicated	Men, pregnancy, catheters, obstruction	Recurrent/severe UTI

3. Drugs Used in UTI

A. Urinary Tract Antiseptics/Antimicrobials (act primarily in urine)

These drugs achieve effective concentrations in the urine but NOT in systemic tissues - hence they are only used for lower UTI (cystitis), not pyelonephritis.

1. Nitrofurantoin

Mechanism of action: Converted intracellularly by bacterial reductases to highly reactive intermediates that nonspecifically damage ribosomal proteins, and inhibit DNA, RNA, and protein synthesis. The mechanism is not fully understood - multiple bacterial targets are affected simultaneously, which is why resistance emerges very slowly.

Spectrum:

Bactericidal against gram-negative (E. coli, Klebsiella) and gram-positive (Enterococcus, Staphylococcus) urinary pathogens
Proteus spp. and Pseudomonas aeruginosa are intrinsically resistant

Pharmacokinetics:

Well absorbed orally; rapidly metabolized and excreted
Achieves urinary concentrations ~200 mcg/mL - no systemic antibacterial action
Excreted via glomerular filtration AND tubular secretion
Drug activity is enhanced at urine pH <5.5 (acidic urine)
Formulations: macrocrystals (4x/day) vs macrocrystals + monohydrate combination (2x/day, Macrobid)

Dose: 100 mg orally 4 times/day (or 100 mg BD as long-acting preparation)

Adverse effects:

Common: Anorexia, nausea, vomiting, diarrhea
Serious (prolonged use >1 month): Pulmonary fibrosis, peripheral neuropathy, autoimmune hepatitis
Hemolytic anemia in G6PD-deficient patients
Hypersensitivity: rashes, pulmonary infiltrates

Contraindications:

Significant renal insufficiency (CrCl <30-60 mL/min) - ineffective AND toxic
Pyelonephritis or upper UTI (inadequate tissue levels)
G6PD deficiency

Key exam point: Nitrofurantoin is currently first-line for uncomplicated cystitis (5-day course), especially as resistance to TMP-SMX and fluoroquinolones has increased.

2. Methenamine (Methenamine Mandelate / Methenamine Hippurate)

Mechanism of action: Methenamine is a pro-drug. In acidic urine (pH ≤ 5.5), it hydrolyzes to release formaldehyde (HCHO) + ammonia. Formaldehyde is a non-specific bactericidal agent that denatures bacterial proteins and nucleic acids.

Methenamine mechanism - formaldehyde release at low urine pH

Methenamine decomposes to 6 formaldehyde molecules + 4 NH4+ at acidic urine pH - Lippincott Pharmacology

Formulations:

Methenamine mandelate - combined with mandelic acid (keeps urine acidic)
Methenamine hippurate - combined with hippuric acid (preferred in renal insufficiency as mandelic acid precipitates in renal failure)

Spectrum:

Active against E. coli, Enterococcus, Staphylococcus
Limited against Proteus - because Proteus produces urease, which alkalinizes urine, blocking formaldehyde release
No resistance development (bacteria cannot develop resistance to formaldehyde)

Use: Chronic suppressive therapy to reduce frequency of recurrent UTIs. NOT used for acute treatment.

Adverse effects:

GI distress (most common)
High doses: albuminuria, hematuria, rash

Important drug interaction:

Do NOT combine with sulfonamides (TMP-SMX) - increases crystalluria risk AND mutual antagonism

Contraindication: Renal insufficiency (with mandelate salt - mandelic acid precipitates)

3. Fosfomycin

Mechanism of action: Inhibits enolpyruvyl transferase (MurA enzyme) - a key early step in peptidoglycan (bacterial cell wall) synthesis. Also reduces bacterial adherence to urinary epithelium.

Use: First-line for acute uncomplicated cystitis, given as a single oral dose (3g sachet). Particularly useful against multidrug-resistant E. coli and Enterococcus faecalis (including VRE).

Key exam point: Single-dose treatment = fosfomycin.

4. Systemic Antibiotics Used for UTI

These are used for both lower and upper UTI (pyelonephritis):

A. Trimethoprim-Sulfamethoxazole (Co-trimoxazole / TMP-SMX)

Mechanism - Sequential folate blockade (double blockade):

Drug	Enzyme Inhibited	Step Blocked
Sulfamethoxazole (sulfonamide)	Dihydropteroate synthetase	Competes with PABA - blocks conversion of PABA → dihydrofolic acid
Trimethoprim	Dihydrofolate reductase (DHFR)	Blocks conversion of dihydrofolic acid → tetrahydrofolic acid

This sequential blockade produces a synergistic bactericidal effect - bacteria cannot synthesize purines/thymidine and die.

Spectrum: Broad gram-negative coverage including E. coli, Klebsiella, Proteus, Enterobacteriaceae

Use: Uncomplicated cystitis (3-day course); avoid if local E. coli resistance >20%

Adverse effects:

Nausea, vomiting, skin rash
Hematologic toxicity (megaloblastic anemia - folate depletion)
Hyperkalemia
Crystalluria (with sulfonamide component)
Stevens-Johnson syndrome (rare but serious)
Teratogenic - avoid in 1st trimester and near term

B. Fluoroquinolones

Mechanism:

Inhibit DNA gyrase (topoisomerase II) in gram-negative bacteria
Inhibit topoisomerase IV in gram-positive bacteria
Both are type II topoisomerases; inhibition prevents DNA supercoil relaxation, causing DNA strand breaks and cell death - bactericidal

Drugs used for UTI:

Ciprofloxacin - best gram-negative coverage; used for complicated UTI and pyelonephritis
Levofloxacin - broader spectrum, once daily
Norfloxacin - primarily urinary concentrations only; for uncomplicated UTI (note: this is now largely replaced)
Ofloxacin - urinary tract infections

Pharmacokinetics: High oral bioavailability, excellent tissue penetration, good urinary concentrations - can be used for upper UTI/pyelonephritis.

Adverse effects:

Nausea, vomiting, photosensitivity
QT prolongation (cardiac risk)
Black box warnings: Tendinitis/tendon rupture, peripheral neuropathy, CNS effects (seizures, psychiatric)
Avoid in children and pregnancy (cartilage damage in growing animals)
Chelation with antacids, Ca2+, Mg2+, Fe2+ (reduce absorption)

Current status: Due to rising resistance and serious adverse effects, fluoroquinolones are now reserved for complicated UTI/pyelonephritis where alternatives are not suitable. They are NO longer preferred first-line for uncomplicated cystitis.

C. Beta-Lactams

Amoxicillin-Clavulanate:

Active against E. coli producing beta-lactamase
Used in pregnancy (safe)

Cephalosporins (e.g., Cephalexin, Cefixime):

Used for uncomplicated UTI and during pregnancy
Ceftriaxone IV for severe pyelonephritis

D. Aminoglycosides (Gentamicin, Amikacin)

Reserved for severe/complicated UTI and hospital-acquired infections
Gentamicin IV/IM for pyelonephritis
Narrow therapeutic index - monitor renal function and drug levels

5. Treatment Summary (Current First-Line)

Indication	Drug of Choice	Duration
Uncomplicated cystitis (women)	Nitrofurantoin	5 days
Uncomplicated cystitis	Fosfomycin	Single dose
Uncomplicated cystitis	TMP-SMX (if resistance <20%)	3 days
Pyelonephritis (mild-moderate)	Ciprofloxacin / Levofloxacin	7-14 days
Pyelonephritis (severe)	IV Ceftriaxone / Aminoglycoside	14 days
Pregnancy UTI	Cephalexin / Amoxicillin-Clav / Nitrofurantoin*	7 days
Chronic suppression	Methenamine / Nitrofurantoin low dose	Long-term
Complicated/ESBL UTI	Fosfomycin / Meropenem	Per culture

*Avoid nitrofurantoin near term (38-42 weeks) due to risk of neonatal hemolysis.

6. Key Pharmacology Points for Exam

Nitrofurantoin - inhibits DNA/RNA synthesis; first-line for cystitis; NOT for pyelonephritis; causes pulmonary fibrosis with long use; contraindicated in renal failure
Methenamine - prodrug; releases formaldehyde in acidic urine (pH <5.5); chronic suppression only; no resistance; avoid with sulfonamides
Fosfomycin - inhibits MurA (cell wall); single dose; for uncomplicated cystitis
TMP-SMX - double/sequential folate blockade (sulfonamide blocks DHPS; trimethoprim blocks DHFR); 3-day course; avoid in areas of >20% resistance
Fluoroquinolones - inhibit DNA gyrase (GNB) and topoisomerase IV (GPB); now reserved for pyelonephritis; black box: tendon rupture
Proteus raises urine pH - makes methenamine and nitrofurantoin less effective
G6PD deficiency - avoid nitrofurantoin (hemolytic anemia)
Single-dose = Fosfomycin; avoid single-dose nitrofurantoin and beta-lactams (high recurrence)

Sources: Katzung's Basic and Clinical Pharmacology 16th Ed; Lippincott Illustrated Reviews: Pharmacology

This is a shared conversation. Sign in to Orris to start your own chat.